Cogent Biosciences (COGT) Gains from Investment Securities (2017 - 2026)

Cogent Biosciences' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at -$135000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 109.42% year-over-year to -$135000.0; the TTM figure through Mar 2026 stood at -$27.4 million (down 2010.79% YoY), while the FY2025 annual figure was $340000.0, down 87.47% from the prior year.
• Gains from Investment Securities was -$135000.0 for Q1 2026 at Cogent Biosciences, down from $340000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $15.5 million in Q4 2023 to a low of -$24.2 million in Q4 2022.
• Historically, Gains from Investment Securities has averaged $541481.5 across 5 years, with a median of $796715.0 in 2023.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities plunged 810.72% in 2022, then surged 456.25% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at -$24.2 million in 2022, then jumped by 164.1% to $15.5 million in 2023, then sank by 82.49% to $2.7 million in 2024, then plunged by 87.47% to $340000.0 in 2025, then plunged by 139.71% to -$135000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$135000.0 (Q1 2026), $340000.0 (Q4 2025), and $302733.0 (Q3 2025), per Business Quant data.